Incidence and clinical predictors of subsequent atrial fibrillation requiring additional ablation after cavotricuspid isthmus ablation for typical atrial flutter.

OBJECTIVES: We sought to investigate the incidence of atrial fibrillation after catheter ablation for typical atrial flutter and to determine the predictors for symptomatic atrial fibrillation that required a further additional dedicated ablation procedure. DESIGN: 127 patients underwent elective cavotricuspid isthmus ablation with the indication of symptomatic, typical atrial flutter. The occurrence of atrial flutter, atrial fibrillation, cerebrovascular events and the need for additional ablation procedures for symptomatic atrial fibrillation was assessed during long-term follow-up. RESULTS: The majority of patients (70%) manifested atrial fibrillation during a follow-up period of 68 ± 24 months, and a significant proportion (42%) underwent one or multiple atrial fibrillation ablation procedures after an average of 26 months from the index procedure. Recurrence of typical atrial flutter was rare. Ten patients (8%) suffered cerebrovascular events. Earlier documentation of atrial fibrillation (OR 3.53), previous use of flecainide (OR 3.33) and left atrial diameter (OR 2.96) independently predicted occurrence of atrial fibrillation during the follow-up. A combination of pre- and intra-procedural documentation of atrial fibrillation (OR 3.81) and previous use of flecainide (OR 2.43) independently predicted additional atrial fibrillation ablation. DISCUSSION: Atrial fibrillation occurred in the majority of patients after ablation for typical atrial flutter and 42% of them required an additional dedicated ablation procedure. Pre- and intraprocedural documentation of atrial fibrillation together with previous use of flecainide independently predicted atrial fibrillation occurrence and a need for additional ablation. Anticoagulation treatment should be continued in high-risk patients in spite of clinical disappearance of atrial flutter.

Effect of flecainide on the extension and localization of complex fractionated electrogram during atrial fibrillation.

AIMS: Complex fractionated electrogram (CFE) ablation in addition to pulmonary vein isolation is an accepted strategy for the treatment of non-paroxysmal atrial fibrillation (AF). We sought to determine the effect of flecainide on the distribution and extension of CFE areas. METHODS: Twenty-three non-paroxysmal AF patients were enrolled in this prospective study. A first CFE map was obtained under baseline conditions by sampling 5 s of continuous recording from the distal electrodes of the ablation catheter. Intravenous flecainide (1 mg/kg) was administered over 10 min and followed by 30-min observation time. A second CFE map was obtained with the same modalities. CFE-mean values, CFE areas, and atrial electrogram amplitude were retrieved from the electro-anatomical mapping system (Ensite NavX). RESULTS: After flecainide administration, CFE-mean values increased (111.5 ± 55.3 vs. 132.3 ± 65.0 ms, p < 0.001) with a decrease of CFE area (32.9%) in all patients. Atrial electrogram amplitude decreased significantly (0.30 ± 0.31 vs. 0.25 ± 0.20 mV, p < 0.001). We observed 80.9% preservation of CFE areas. A CFE mean of 78 ms was the best cutoff for predicting stable CFE areas. CONCLUSIONS: Flecainide reduces the extension of CFE areas while preserving their spatial localization. A CFE-mean value <80 ms may be crucial to define and locate stable CFE areas.

Ablation effect indicated by impedance fall is correlated with contact force level during ablation for atrial fibrillation.

INTRODUCTION: Previous studies have validated the use of impedance fall as a measure of the effects of ablation. We investigated whether catheter-to-tissue contact force correlated with impedance fall during atrial fibrillation ablation. METHODS AND RESULTS: A total of 394 ablation points from 35 patients who underwent atrial fibrillation ablation were selected and analyzed in terms of the presence of stable catheter contact in non-ablated areas in the left atrium. A fixed power output (30 W) was applied for 60 seconds. Contact force, impedance fall, and force-direction angle were retrieved and exported for off-line analysis. Qualified points were divided into 5 groups according to the level of contact force (1-5 g, 6-10 g, 11-15 g, 16-20 g, and >20 g). An acute impedance fall was observed in the first 10 seconds followed by a plateau in group I and by a further fall in the other groups. Group V showed a rise in impedance during the last 20 seconds of ablation. Levels of impedance fall at each time point were significantly different among all the groups (P<0.001) except between groups III and IV. There was a significant correlation between contact force and maximum impedance fall (rho = 0.54, P<0.01). Lesions with a force-direction angle of 0-30° had significantly lower contact force and maximum impedance fall than those with angles of 30-60° and 60-135° (P<0.01). CONCLUSIONS: Under stable catheter conditions, contact force correlates with impedance fall during 60 seconds of ablation. Contact force exceeding 5 g produces greater impedance fall, which probably indicates adequate lesion formation. A contact force greater than 20 g may lead to late tissue overheating.

Ventricular arrhythmias originating from the aortomitral continuity: an uncommon variant of left ventricular outflow tract tachycardia.

AIMS: Ventricular arrhythmias arising from the fibrous rings have been demonstrated, but knowledge about the aortomitral continuity (AMC) as a source of the arrhytmias is still limited. The objective is to describe the characteristics of ventricular arrhythmias originating from the AMC in patients without structural heart disease. METHODS AND RESULTS: Ten patients with ventricular tachycardia (VT) and/or premature ventricular contractions, who had been successfully treated by catheter ablation at the AMC beneath the aortic valve, were enrolled. Clinical data and electrocardiographic characteristics were analysed. Three of the 10 patients had previously registered episodes of supraventricular tachycardia and had undergone catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT). In four patients with anterior AMC location, early R/S wave transition was found in the precordial leads, with equal R and S amplitudes in V2, rS in V1, and R in V3. In six patients whose VT arose from the middle part of the AMC, we demonstrated a special ('rebound') transition pattern, with which equal R and S amplitudes occurred in V2, and high R waves in V1 and V3. In the anterior AMC location, the S/R ratios in leads V1 and V2 were >1 and statistically significantly higher than those located in the middle (V1: 1.59 vs. 0.23, P< 0.001; V2: 1.52 vs. 0.41, P< 0.01). CONCLUSIONS: We report a series of ventricular arrhythmias arising from the AMC with different R/S wave transition patterns in the precordial leads on the electrocardiogram. There may be a relationship between ventricular arrhythmias from AMC and AVNRT.

[Magnetic navigation for ablation of cardiac arrhythmias]. / Magnetstyrt ablasjonsbehandling av hjerterytmeforstyrrelser.

BACKGROUND: The first use of magnetic navigation for radiofrequency ablation of supraventricular tachycardias, was published in 2004. Subsequently, the method has been used for treatment of most types of tachyarrhythmias. This paper provides an overview of the method, with special emphasis on usefulness of a new remote-controlled magnetic navigation system. MATERIAL AND METHODS: The paper is based on our own scientific experience and literature identified through a non-systematic search in PubMed. RESULTS: The magnetic navigation system consists of two external electromagnets (to be placed on opposite sides of the patient), which guide an ablation catheter (with a small magnet at the tip of the catheter) to the target area in the heart. The accuracy of this procedure is higher than that with manual navigation. Personnel can be quickly trained to use remote magnetic navigation, but the procedure itself is time-consuming, particularly for patients with atrial fibrillation. The major advantage is a considerably lower radiation burden to both patient and operator, in some studies more than 50 %, and a corresponding reduction in physical strain on the operator. The incidence of procedure-related complications seems to be lower than that observed with use of manually operated ablation catheters. Work is ongoing to improve magnetic ablation catheters and methods that can simplify mapping procedures and improve efficacy of arrhythmia ablation. The basic cost for installing a complete magnetic navigation laboratory may be three times that of a conventional electrophysiological laboratory. INTERPRETATION: The new magnetic navigation system has proved to be applicable during ablation for a variety of tachyarrhythmias, but is still under development.

Spatial relationships between the pulmonary veins and sites of complex fractionated atrial electrograms during atrial fibrillation.

BACKGROUND: Pulmonary vein (PV) isolation is used for the treatment of atrial fibrillation (AF). Complex fractionated atrial electrogram (CFAE) mapping has been introduced to guide AF ablation. However, the spatial relationship between PV and CFAE is not well defined. METHODS AND RESULTS: The study included 21 patients (mean age 57 +/- 11 years, 17 men, 14 paroxysmal, two persistent, and five long-standing persistent AF) referred for PV isolation. Electrograms were sampled for 8 seconds at each site during stable AF (13 induced). High-frequency was defined as <80 ms of CFAE value. The distance between CFAE and the nearest PV ostium was measured. The PV ostia and antra were demarcated by fluoroscopy guidance and endocardial reconstruction. Among 82 PV mapped (left common four, superior 17, inferior 17; right superior 21, inferior 21, middle 2), 52.4% and 25.6% of high-frequency CFAE were located on the anterior and posterior walls, respectively, inside the PV or at the ostium. No high-frequency CFAE was observed in two out of 60 and one out of 20 PV anteriorly, versus seven out of 60 and 11 out of 20 PV (P < 0.001) posteriorly, in paroxysmal and persistent AF, respectively. In the PV with high-frequency CFAE, the mean shortest distances to the PV ostia in paroxysmal versus persistent AF were 2.7 +/- 5.1 versus 7.4 +/- 5.4 mm anteriorly (P < 0.01), and 6.5 +/- 6.4 versus 9.4 +/- 8.4 mm posteriorly (ns). CONCLUSIONS: During PV isolation, extending the ablation lesions by up to 10 mm from the PV ostia might cover most high-frequency CFAE around the PV antra. High-frequency CFAE were more often located in the PV ostia in paroxysmal than in persistent AF.

Atrio-pulmonary vein conduction delay during pulmonary vein isolation for atrial fibrillation is related to vein anatomy, age, and focal activity.

BACKGROUND: During pulmonary vein isolation for treatment of atrial fibrillation (AF), a significant delay in atrio-pulmonary vein (PV) conduction is often observed. We sought to investigate this conduction delay in various PV in individual patients. METHODS: We studied 385 AF patients (mean age: 54 +/- 11 years, 74 women) who underwent segmental PV isolation (PVI). A circular decapolar catheter was used to record electrograms at the PV ostia. The time delay from local atrial potential to PV potential was measured in each vein. Conduction delay (CD) was defined as the longest time interval >20 ms observed during PVI. RESULTS: For patients treated for the first time, CD was more frequently observed in the left common and the right and left superior PVs (84.2%, 67.9%, and 66.2%, respectively) and less frequently in the left and right inferior and right middle PVs (54.3%, 40.0%, and 30.8%, respectively). Veins with CD required more ablation applications (12.4 vs 9.9) and a higher ablated segmental fraction (72.3% vs 63.7%). CD was observed in 75.2% (109/145) of the PVs in which focal activity was detected. Older patients had a higher incidence of PVs with CD than younger patients. There were no gender differences. CONCLUSIONS: The incidence of CD was highest in the left common and superior PVs, in older patients and in PVs with focal activity. PVs with CD required more ablation applications and a larger area of ablation around the ostia. These observations were not found during repeat procedures.

[Catheter ablation of tachyarrhythmias in children and adolescents]. / Ablasjonsbehandling av takyarytmier hos barn og unge.

BACKGROUND: Catheter ablation has been increasingly applied in children and adolescents with tachyarrhythmias. The aim of this article is to assess the results of ablation therapy of tachycardias in patients below 18 years of age at Haukeland University Hospital. MATERIAL AND METHODS: 141 patients (70 boys and 71 girls, aged 5-17 (13.5 +/- 3.5 ) years with tachyarrhythmias underwent an electrophysiologic study and catheter ablation in the period 1992-2007. RESULTS: Ablation was successfully performed in 138/141 (98%) patients., The procedure was repeated (3 patients twice) until the arrhythmia substrate disappeared in 16 of 138 patients. 81/141 (57%) patients had accessory pathways; 52 (37%) had double atrioventricular nodal pathways, 48 had concealed and 33 patients had overt (classical Wolff-Parkinson-White-syndrome) atrioventricular pathways. 8 (6%) patients had other atrial or ventricular tachyarrhythmias and 4 (3%) had organic heart disease. Use of a 3D mapping system was decisive for success for ablation in patients with complex cardiac diseases. Procedure-related complications were observed in 2/141 (1.4%) patients of whom one had a temporary third degree and one had a permanent first-degree atrioventricular block which did not entail further treatment. CONCLUSION: Catheter ablation of tachycardia in children and adolescents is a safe treatment method with a high success rate and few complications and should be preferred before drug therapy.

Treatment of atrial fibrillation by silencing electrical activity in the posterior inter-pulmonary-vein atrium.

AIMS: The recurrence of atrial fibrillation (AF) after pulmonary vein (PV) isolation is still a challenge. We investigated a new approach to treating AF patients by silencing electrical activity in the posterior inter-pulmonary-vein atrium (PIA). METHODS AND RESULTS: Three ablation steps are required to obtain PIA electrical silence: electrical PV isolation, the creation of two lines of lesions between the two superior and inferior PVs and the abolition of residual electrical signals within the PIA. The endpoint was the electrical silence and the inability to pace in the PIA. The posterior inter-pulmonary-vein atrium silence was obtained in 42 AF patients (56 +/- 9 years, four women). Recurrence of AF and atrial flutter was observed in 14 (33.3%) patients after the first procedure. Freedom from atrial arrhythmias after the second procedure was displayed by 94.4, 85.7, and 60.0% of patients with paroxysmal, persistent, and permanent AF, respectively. The left atrium (LA) volume was larger, and the percentages of the silent area of the LA surface and voltages were lower in patients with AF recurrence than in recurrence-free patients. CONCLUSION: Posterior inter-pulmonary-vein atrium electrical silence can greatly decrease the AF recurrence. The clinical AF recurrence may be related to an enlarged LA, a low percentage of electrically silent area, and low voltage in the LA.

Reducing atrial tachycardia and atrial fibrillation episodes with a prevention and treatment device and tailored treatment.

BACKGROUND: Pacemaker treatment of known trigger mechanisms for atrial tachyarrhythmias (AT) and atrial fibrillation (AF) has shown reduction in the incidence of AF. A new arrhythmia management device, which included storage of AT/AF (for tailoring treatment) and three prevention algorithms and one for treatment, was examined in order to identify the influence on arrhythmia episodes over a 12-month follow-up (FU) period. METHODS: Twenty-three consecutive patients with known tachybradyarrhythmias were examined. Seven patients had to be excluded (two outliers, four developed permanent AF, one had no detection algorithm turned on at implantation). The remaining 16 patients showed 2723 episodes (675 treated episodes) for evaluation of the effect on episodes/month/patient (e/m/p), treatment success, duration of episodes, circadian distribution and quality of life. RESULTS: The AT/AF e/m/p were reduced from 37 +/- 102 e/m/p at 1-month FU to 16 +/- 48 e/m/p at 3-month FU, 15 +/- 48 e/m/p at 6-month FU and 10 +/- 28 e/m/p at 12-month FU (p < 0.05), according to fewer subjective symptoms. Treatment success remained stable during the observation period (29-40%). Only minor changes in the duration of episodes and the distribution of start times were observed. CONCLUSION: Tailoring treatment by the pacemaker examined with several prevention and treatment algorithms reduces e/m/p and might be a promising supplement in the treatment of selected patients with known AT/AF and bradycardia.

Device treatment of atrial tachycardia--minor additional effect of repeating pacing sequences.

PURPOSE: Ramp and burst pacing as treatment for atrial tachycardia (AT), one known trigger mechanism of atrial fibrillation (AF) are available in permanent pacemakers to reduce the burden of AF. An analysis of the success rate of three consecutive antitachycardia pacing sequences is presented. METHOD: The AT 500 (Medtronic) pacemaker was implanted in 36 patients (18 female, mean age 77+/-11 years) with pacemaker indication due to tachybrady arrhythmias (n=34), and other indications (n=2). A standardized AT treatment of 8 sequences of ramp followed by six and four sequences burst pacing was programmed on after 1 month of tachycardia detection only. 5 consecutive sinus beats or 3 min with atrial rhythm not classified as AF or AT defined treatment success and was registered at 3 months follow-up. RESULTS: 2979 episodes (mean 85+/-316) in 17 patients (7 female) were treated and analyzed. The overall treatment success increased from 42+/-27% to 44+/-31% and 45+/-31% during the consecutive ATP sequences (ns). The average ATP success of the first ramp pacing sequences was 95+/-10%, the second ramp ATP sequence was successful in 3+/-6%, and the last ramp ATP sequence in 2+/-5%. CONCLUSION: 95% of the 45% treatment success of a standard AT treatment was achieved by the first ramp pacing sequence. Further antitachycardia pacing sequences did not increase the success rate significantly.

Identification of extremely slow conduction in the cavotricuspid isthmus during common atrial flutter ablation.

INTRODUCTION: Complete isthmus block has been used as an endpoint for radiofrequency ablation for common atrial flutter (AF). We sought to systematically evaluate extremely slow conduction (ESC), which is easily misinterpreted as complete block. METHODS AND RESULTS: We studied 107 consecutive patients (92 men, 15 women, 58 +/- 11 years) who had undergone a successful AF ablation procedure. A 24-pole catheter was positioned along the tricuspid annulus spanning the isthmus. Complete isthmus block was defined as the presence of a complete corridor of double potentials along the ablation line. Activation delay time (AT), activation difference (deltaA) between two adjacent dipoles, maximum activation difference (deltaA(max)), change in polarity (CP) and change in amplitude (CA) of the bipolar atrial electrogram were recorded and P-wave morphology in the surface electrocardiogram was analyzed. ESC was observed in 16 patients. Between ESC and complete block, differences were found on the two lateral dipoles adjacent to the ablation line (AT: 148 +/- 17 vs. 183 +/- 27 ms and 155 +/- 18 vs. 170 +/- 28 ms, P < 0.01; deltaA: -91 +/- 22 vs. -126 +/- 28 ms and -7 +/- 13 vs. 13 +/- 6 ms, P < 0.01). Statistically significant differences in CP were detected on the relevant dipoles (7/16 vs. 14/16 and 6/16 vs.13/16, P < 0.05). No significant difference was found either in CA or in terminal P wave positivity. Mean deltaA(max) were 13.8 +/- 5.0 and 27.8 +/- 9.5 ms (P < 0.001) respectively in ESC and complete block. Two types of ESC, regular and irregular, were demonstrated during the ablation procedure. CONCLUSIONS: (1) ESC was observed in 15% of the patients during the AF ablation procedure. (2) The parameters of AT, deltaA, and CP may help to differentiate ESC from complete block. DeltaA(max) might be the most powerful indicator. (3) To verify complete block, it is essential to position the mapping catheter across the CTI in order to demonstrate the activation sequence up to the ablation line.

[Curative treatment of paroxysmal atrial fibrillation with radiofrequency ablation]. / Kurativ behandling av paroksysmal atrieflimmer med radiofrekvensablasjon.

BACKGROUND: Atrial fibrillation is associated with increased morbidity and twice the mortality compared to individuals without fibrillation. Treatment with antiarrhythmic drugs has limited effect in paroxysmal atrial fibrillation. MATERIAL AND METHOD: The group of patients comprised 59 men and 13 women with an average age of 51 +/- 10, the majority of whom had failed several drug regimens; some had undergone repeated DC conversions. A new method based on radiofrequency ablation and isolation of pulmonary veins from the left atrium may offer curative treatment for paroxysmal atrial fibrillation. The basis for this method is that foci in or close to the pulmonary veins initiate or drive atrial fibrillation. These foci may be identified by transseptal access to the left atrium and isolation of the veins from the left atrium using radiofrequency energy. RESULTS: The group of 72 patients underwent 86 procedures. Foci were observed in 65.3%. Isolation of 3.1 +/- 0.9 veins was performed in 71 patients. During a follow up period of 10.3 +/- 5.1 months, 60.9% reported absence of fibrillation and 81.2% reported cure or considerable improvement. Complications included drainage of pericardial effusion in one patient, cerebral embolus with partial visual impairment in one patient, and an asymptomatic pulmonary vein stenosis in one patient. CONCLUSION: Paroxysmal atrial fibrillation can be treated in selected patients using pulmonary vein isolation with low to moderate risk of complications. Longer follow up is necessary for full evaluation of effect.

Long-term outcomes of adjunctive complex fractionated electrogram ablation to pulmonary vein isolation as treatment for non-paroxysmal atrial fibrillation.

PURPOSE: The adjunctive ablation of areas of complex fractionated electrogram (CFE) to pulmonary vein isolation (PVI) is an emerging strategy for patients with non-paroxysmal atrial fibrillation (AF). We studied the long-term outcomes of this approach. METHODS: Sixty-six patients (mean age 58 ± 9, 86.4 % male) with non-paroxysmal AF underwent ablation procedures consisting of PVI plus extensive CFE ablation. Post-ablation atrial tachycardia (AT) was also targeted if presented. All patients were followed up regularly on an ambulatory basis by means of ECG and Holter recordings. RESULTS: After a mean follow-up period of 40 ± 14 months and 1.7 ± 0.7 procedures, 38 patients (57.6 %) were free of arrhythmias, 15 (22.7 %) displayed clinical improvement and 13 (19.7 %) suffered recurrences of persistent AF/AT. Females displayed poorer long-term outcomes than males (arrhythmia-free 22.2 vs. 63.2 %, p < 0.05). Multivariate analysis demonstrated that long duration of uninterrupted AF prior to the procedure was an additional predictor of long-term failure (odds ratio 1.49, p < 0.01). ROC analysis (area under curve 0.80; p < 0.001) estimated 3.5 years as the optimal cut-off point for predicting long-term failure (sensitivity 85 %, specificity 74 %). The cumulative data showed a significantly higher percentage of arrhythmia-free patients when the duration of AF had been ≤ 2 years (69.7 %) and ≤ 4 years (68.9 %) than when it was > 4 years (33.3 %; p < 0.01). CONCLUSIONS: PVI + CFE ablation in non-paroxysmal AF appears to provide a reasonable proportion of arrhythmia-free patients during long-term follow-up. Poorer long-term results can be expected among female patients and those with an uninterrupted AF duration of > 4 years.

N-terminal pro-B-type natriuretic peptide level at long-term follow-up after atrial fibrillation ablation: a marker of reverse atrial remodelling and successful ablation.

AIMS: We investigated the relationship between arrhythmia burden, left atrial volume (LAV) and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) at baseline and after long-term follow-up of atrial fibrillation (AF) ablation. METHODS: We studied 38 patients (23 paroxysmal, 6 women, mean age 56 ± 11) scheduled for AF ablation. LAV was calculated on the basis of computed tomography images at baseline and long-term follow-up, and arrhythmia burden was graded from self-reported frequency and duration of AF episodes. RESULTS: After a mean period of 22 ± 5 months, 28/38 patients (11/15 persistent) were free from AF recurrence. At baseline there were no differences in mean LAV (125 vs. 130 cm(3), p = 0.7) or median NT-pro-BNP (33.5 vs. 29.5 pmol/L, p = 0.9) between patients whose ablation had been successful or otherwise. At long-term follow-up, there was a marked decrease in LAV (105 vs. 134 cm(3), p < 0.05) and level of NT-pro-BNP (7 vs. 17.5 pmol/L, p < 0.05) in the successful ablation patients. NT-pro-BNP correlated with LAV both at baseline (r = 0.71, p < 0.001) and at follow-up (r = 0.57, p < 0.001). Arrhythmia burden correlated with both NT-pro-BNP (r = 0.47, p < 0.01) and LAV (r = 0.52, p < 0.01). A decrease in NT-pro-BNP at follow-up of >25% of baseline value had a specificity of 0.89 and a sensitivity of 0.6 (receiver operator characteristics, accuracy 0.82) for ablation success. CONCLUSIONS: NT-pro-BNP correlates with LAV and arrhythmia burden in AF patients and both NT-pro-BNP and LAV decrease significantly after successful ablation. A decrease in NT-pro-BNP of >25% from the baseline value could be useful as a marker of ablation success.

Remote magnetic versus manual catheters: evaluation of ablation effect in atrial fibrillation by myocardial marker levels.

BACKGROUND: A remote magnetic navigation (MN) system is available for radiofrequency ablation of atrial fibrillation (AF), challenging the conventional manual ablation technique. The myocardial markers were measured to compare the effects of the two types of MN catheters with those of a manual-irrigated catheter in AF ablation. METHODS: AF patients underwent an ablation procedure using either a conventional manual-irrigated catheter (CIR, n = 65) or an MN system utilizing either an irrigated (RMI, n = 23) or non-irrigated catheter (RMN, n = 26). Levels of troponin T (TnT) and the cardiac isoform of creatin kinase (CKMB) were measured before and after ablation. RESULTS: Mean procedure times and total ablation times were longer employing the remote magnetic system. In all groups, there were pronounced increases in markers of myocardial injury after ablation, demonstrating a significant correlation between total ablation time and post-ablation levels of TnT and CKMB (CIR r = 0.61 and 0.53, p < 0.001; RMI r = 0.74 and 0.73, p < 0.001; and RMN r = 0.51 and 0.59, p < 0.01). Time-corrected release of TnT was significantly higher in the CIR group than in the other groups. Of the patients, 59.6% were free from AF at follow-up (12.2 ± 5.4 months) and there were no differences in success rate between the three groups. CONCLUSIONS: Remote magnetic catheters may create more discrete and predictable ablation lesions measured by myocardial enzymes and may require longer total ablation time to reach the procedural endpoints. Remote magnetic non-irrigated catheters do not appear to be inferior to magnetic irrigated catheters in terms of myocardial enzyme release and clinical outcome.

Characteristics and distribution of complex fractionated atrial electrograms in patients with paroxysmal and persistent atrial fibrillation.

INTRODUCTION: Substrate-based radiofrequency ablation for treatment of atrial fibrillation (AF) is still under development. The purpose of this study was to investigate the different characteristics and distribution of complex fractionated atrial electrograms (CFAE) in both atria in patients with paroxysmal and persistent AF. METHODS AND RESULTS: The NavX system was used to map the left and right atria and the coronary sinus in 20 AF patients (ten persistent). An automated algorithm calculates the average time interval between consecutive deflections (complex fractionated electrogram (CFE) mean). All recordings were visually inspected off-line and interpreted either as continuous, fragmented, mixed CFAE, or non-CFAE, and their locations were determined. Electrograms with intermittent CFAE characteristics were also regarded as non-CFAEs. There were more CFAEs in persistent AF than in paroxysmal AF (52% vs. 44% of total registrations, p < 0.05), and CFAEs were more widespread in both atria in persistent AF patients. There were also more continuous CFAEs (70% vs. 59% of total CFAEs, p < 0.05), and less mixed and intermittent CFAEs (22% vs. 30% and 16% vs. 21% of total CFAEs, respectively, p < 0.05) in persistent AF. Fragmented CFAEs had more high-voltage signals than other groups. Employing the automated algorithm for CFAE mapping, a CFE mean cut-off value of < or =80 ms provides a sensitivity and specificity of 87.4% and 81.2%, respectively. CONCLUSIONS: CFAEs distribute in preferential areas and arrange in different patterns in both atria. Patients with persistent AF have more continuous CFAEs and higher temporal signal stability than patients with paroxysmal AF.

Electroanatomical mapping and radiofrequency catheter ablation of atrial tachycardia originating from the donor heart after orthotopic heart transplantation in a child.

A 15-year-old boy who had been given an orthotopic heart transplant 12 years earlier underwent radiofrequency ablation after 14 months of tachycardia. At the time of the procedure, the patient presented moderate signs of heart failure and tachycardia-induced cardiomyopathy. During electroanatomical mapping we identified a focal atrial tachycardia with origin in the donor right atrium and bi-directional atrio-atrial conduction. After successful focal ablation the patient had two alternating atrial activation patterns, representing the recipient and the donor heart sinus rhythm. Two months after the ablation heart failure symptoms were in regress, and the patient was still in sinus rhythm.

Significance of late recurrence of atrial fibrillation during long-term follow-up after pulmonary vein isolation.

BACKGROUND AND STUDY OBJECTIVE: Patients with paroxysmal or persistent atrial fibrillation (AF) can be treated by pulmonary vein (PV) isolation. Although the recurrence rate after the procedure is relatively high, the long-term outcomes after initially recurrence-free procedures remains unclear. We examined the rates of recurrence of AF after PV isolation. METHODS: Our study included 278 consecutive patients with drug-refractory AF (mean age = 53 +/- 11 years, 228 men). PV isolation was based on the disappearance of PV potentials recorded from a circumferential catheter after segmental ostium ablation. Cavo-tricuspid isthmus lines and additional atrial lines were performed in 124 and 28 patients, respectively. Patients were monitored for a mean of 26 +/- 11 months (range 12-56). Recurrence was defined as >/= 1 episodes of symptomatic or asymptomatic AF > 1 month after the procedure. RESULTS: A total of 120 (34) patients had >/= 1 recurrence of AF > 1 month after the procedure, of whom 14 (4) had a first recurrence > 6 months after the procedure. There was a significantly higher recurrence rate among patients with persistent AF. CONCLUSIONS: A relatively high AF recurrence rate was observed after PV isolation. AF may recur late after the ablation procedure, though the majority of recurrences occurred within 6 months after the first procedure. There were no differences in incidence or time of occurrence of late recurrences between patients with paroxysmal versus persistent AF.